Currently, Dr. Druker continues to focus on the development of new targeted therapies and improving existing treatments. He is also involved in research aimed at understanding the mechanisms of drug resistance, which remains a significant challenge in cancer therapy. His work at the Knight Cancer Institute involves collaborative efforts to translate laboratory discoveries into clinical applications that benefit patients.
